Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

By W. Curran, R. Paulus, C. Langer, R. Komaki, Jin Lee, Stephen L. Hauser, B. Movsas, T. Wasserman, S. Rosenthal, E. Gore and 3 more. Journal of the National Cancer Institute, 2011

1,159 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/3c316ccad637e3cffb721d29904e00c4e365a3e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Hugo J. W. L. Aerts
2. Philippe Lambin

In Pulmonary and Respiratory Medicine

1. Hugo J. W. L. Aerts
2. Philippe Lambin
3. Chintan Parmar
4. Ahmed Hosny

In Radiology, Nuclear Medicine and Imaging

1. Hugo J. W. L. Aerts
2. Philippe Lambin
3. R. T. Ten Haken
4. Chintan Parmar
5. Ahmed Hosny
6. John Quackenbush

Citations in the corpus

• Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer (2017, positive): “After neoadjuvant chemoradiotherapy in CALGB 9433, 90% of patients failed locally with 45% having local failure alone [4, 5].”
• CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. (2015, background): “Despite the use of concurrent chemotherapy with local therapy, the incidence of DM after combined modality therapy is as high as 30–40% in prospective trials [2–4].”
• Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model (2017, neutral): “= SF Mon SF Mon min ( ( ) ( )) (8) Mon model i observed i 1 60 2”